TRICARE Prior Authorization Request Form for deucravacitinib (Sotyktu)



JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider			
Drug Name:	Strength:		
Dosage/Frequency (SIG):	Duration of Therapy:		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Step	Please complete patient and physician information (please print):						
1	Patient Name: Physician Name:						
•	Ad	Address: Address:					
			one #:				
	Date of Birth: Secure Fax #:						
Step	Ple	Please complete clinical assessment:					
2	1.	Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	☐ Yes Proceed to question 2	☐ No Proceed to question 4			
	2.	Has the patient had an inadequate response to Humira?	☐ Yes Proceed to question 5	☐ No Proceed to question 3			
	3.	Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	☐ Yes Proceed to question 5	□ No STOP Coverage not approved			
	4.	Does the patient have a contraindication to Humira (adalimumab)?	☐ Yes Proceed to question 5	□ No STOP Coverage not approved			
	5.	Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a contraindication to Cosentyx (secukinumab)?	☐ Yes Proceed to question 6	□ No STOP Coverage not approved			
	6.	Is the patient 18 years of age or older?	☐ Yes Proceed to question 7	□ No STOP Coverage not approved			
	7.	What is the diagnosis or indication?	☐ Moderate to severe plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy – Proceed to question 8 ☐ Other indication or diagnosis – STOP: coverage				
	8.	Has the patient had an inadequate response to non-biologic systemic therapy (for example: methotrexate or corticosteroids)?	not approved. □ Yes Proceed to question 9	☐ No STOP Coverage not approved			
	9.	Will the patient be using the requested medication concomitantly with other Targeted Immunomodulatory Biologics (TIB) agents (for example, Enbrel, Remicade)?	☐ Yes STOP Coverage not approved	☐ No Proceed to question 10			

TRICARE Prior Authorization Request Form for deucravacitinib (Sotyktu)

10. Is the provider aware of the FDA safety alerts and warnings and precautions? 11. Has the patient had evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?	Proceed to question 11	STOP
	☐ Yes Sign and date below.	Coverage not approved No STOP Coverage not approved
Step I certify the above is true to the best of my knowledge. F	Please sign and date:	
Prescriber Signature	Date	
		[15 February 2023]
For Internal Use Only		
_	uration of Approval:	_month(s)
	uthorized By:	(0)
☐ Incomplete/Other: PA	<u> </u>	